- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02888522
Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML (IMODLAM)
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is now an effective treatment of Acute Myeloid Leukemia (AML). After allo-HSCT, relapses are the major cause of mortality and occur in about 30% of cases. The occurrence of relapses is important during the first three months post-allogeneic transplant, then gradually decreases during the first year post-allograft and then becomes weaker. After relapse, therapeutic options include the reduction of immunosuppression, the administration of donor lymphocytes (DLI), chemotherapy or a new transplant. The performance is influenced by the early introduction of treatment whose effectiveness is related to the importance of tumor burden. Immunomodulation of preemptive strategies have recently been established by decreasing immunosuppression and achieve DLIs in patients with a high risk of relapse, before the occurrence of relapse.
The aim of this study is to evaluate the incidence of relapse following the recommendations of post-allogeneic transplant immunomodulation of the French society of bone marrow transplantation.
Study Overview
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Caen, France, 14000
- Recruiting
- University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Acute myeloid leukemia
- Allogeneic stem cell transplantation (related or unrelated)
Exclusion Criteria:
- Age under 18 years
- Cord blood transplantation
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of recipient chimerism
Time Frame: 3 months
|
whole blood chimerism
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of relapse at 1 year
Time Frame: Relapse rate at 1 year
|
Relapse rate at 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 15-182
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AML
-
H Scott BoswellTakedaTerminatedAML | AML, AdultUnited States
-
Technische Universität DresdenAbbVieActive, not recruitingRelapsed Adult AML | Refractory AMLGermany
-
Carbiogene Therapeutics Co. Ltd.Zhejiang Provincial People's HospitalRecruiting
-
Hebei Senlang Biotechnology Inc., Ltd.Recruiting
-
Hebei Senlang Biotechnology Inc., Ltd.Recruiting
-
Institute of Hematology & Blood Diseases Hospital...Recruiting
-
Beijing Immunochina Medical Science & Technology...Completed
-
Stichting Hemato-Oncologie voor Volwassenen NederlandWithdrawn
-
National Research Center for Hematology, RussiaFederal Research Clinical Center of Federal Medical & Biological Agency,... and other collaboratorsRecruiting
Clinical Trials on immunomodulation
-
Karolinska InstitutetKarolinska University Hospital; Sahlgrenska University Hospital, Sweden; Region... and other collaboratorsRecruitingAutoimmune Diseases | Allergy | Immunodeficiency | Autoinflammatory Syndrome | Dysregulated Host ResponseSweden
-
Objectif Recherche Vaccins SIDAMerck Sharp & Dohme LLC; Pfizer; Cytheris SACompletedHIV-1 InfectionUnited Kingdom, France, Italy, Spain
-
Erasmus Medical CenterSt. Antonius Hospital; Leiden University Medical Center; Amsterdam UMCCompletedCOVID-19 Acute Respiratory Distress SyndromeNetherlands
-
Mutual Pharmaceutical Company, Inc.Completed
-
Tanta UniversityRecruiting
-
McGill University Health Centre/Research Institute...Completed
-
The University of Hong KongCompletedHelicobacter Pylori InfectionHong Kong